Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: A CYP2B6 gene resequencing study

Pharmacogenetics and Genomics

Volumn 23, Issue 2, 2013, Pages 84-93

  Dobrinas, Maria ^a   Crettol, Séverine ^a   Oneda, Beatrice ^a,c   Lahyani, Rachel ^a   Rotger, Margalida ^a   Choong, Eva ^a   Lubomirov, Rubin ^a,d   Csajka, Chantal ^a,b   Eap, Chin B ^a,b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

CYP2B6; DNA sequencing; methadone; pharmacogenetics; polymorphism

Indexed keywords

CYTOCHROME P450 2B6; METHADONE;

ALLELE; ARTICLE; CYP2B6 GENE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVITY; GENE; GENE MUTATION; GENE SEQUENCE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84873096248     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32835cb2e2     Document Type: Article

References (37)

1. Bertschy G. Methadone maintenance treatment: an update. Eur Arch Psychiatry Clin Neurosci 1995; 245:114-124.
2. Kristensen K, Christensen CB, Christrup LL. The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci 1995; 56:L45-L50.
3. Scott CC, Robbins EB, Chen KK. Pharmacological comparison of the optical isomers of methadone. J Pharmacol Exp Ther 1948; 92:282-286.
4. Eap CB, Crettol S, Rougier JS, Schlapfer J, Sintra GL, Deglon JJ, et al. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther 2007; 81:719-728.
5. Lin C, Somberg T, Molnar J, Somberg J. The effects of chiral isolates of methadone on the cardiac potassium channel IKr. Cardiology 2009; 113:59-65.
6. Stringer J, Welsh C, Tommasello A. Methadone-associated Q-T interval prolongation and torsades de pointes. Am J Health Syst Pharm 2009; 66:825-833.
7. Ansermot N, Albayrak O, Schlapfer J, Crettol S, Croquette-Krokar M, Bourquin M, et al. Substitution of (R, S)-methadone by (R)-methadone: impact on QTc interval. Arch Intern Med 2010; 170:529-536.
8. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet 2002; 41:1153-1193.
9. Gerber JG, Rhodes RJ, Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 2004; 16:36-44.
10. Crettol S, Déglon JJ, Besson J, Croquette-Krokkar M, Gothuey I, Hämmig R, et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19 and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 2005; 78:593-604.
11. Crettol S, Déglon JJ, Besson J, Croquette-Krokkar M, Hämmig R, Gothuey I, et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 2006; 80:668-681.
12. Coller JK, Joergensen C, Foster DJ, James H, Gillis D, Christrup L, et al. Lack of influence of CYP2D6 genotype on the clearance of (R)-, (S)-and racemic-methadone. Int J Clin Pharmacol Ther 2007; 45:410-417.
13. Uehlinger C, Crettol S, Chassot P, Brocard M, Koeb L, Brawand-Amey M, et al. Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients. J Clin Psychopharmacol 2007; 27:273-278.
14. Coller JK, Barratt DT, Dahlen K, Loennechen MH, Somogyi AA. ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin Pharmacol Ther 2006; 80:682-690.
15. Ansermot N, Rudaz S, Brawand-Amey M, Fleury-Souverain S, Veuthey JL, Eap CB. Validation and long-term evaluation of a modified on-line chiral analytical method for therapeutic drug monitoring of (R, S)-methadone in clinical samples. J Chromatogr B 2009; 877:2301-2307.
16. Souverain S, Eap CB, Veuthey JL, Rudaz S. Automated LC-MS method for the fast stereoselective determination of methadone in plasma. Clin Chem Lab Med 2003; 41:1615-1621.
17. Beal SL LB, Sheiner A. NONMEM users guides (1989-2006). Maryland, USA: Icon Development Solutions, Ellicott City; 2007.
18. Lang T, Klein K, Richter T, Zibat A, Kerb R, Eichelbaum M, et al. Multiple novel nonsynonymous CYP2B6 gene polymorphisms in caucasians: demonstration of phenotypic null alleles. J Pharmacol Exp Ther 2004; 311:34-43.
19. National Center for Biotechnology Information-dbSNP. Build 137 for human. Available at: http://www.ncbi.nlm.nih.gov/snp [Accessed 20 February 2012].
20. Home page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee; 2009. Available at: https://www.cypalleles.ki.se [Accessed 20 February 2012].
21. Crettol S, Besson A, Croquette-Krokar M, Hämmig R, Gothuey I, Monnat M, et al. Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:1722-1727.
22. Oneda B, Crettol S, Bochud M, Besson J, Croquette-Krokar M, Hämmig R, et al. b-arrestin2 influences the response to methadone in opioid dependent patients. Pharmacogenomics J 2011; 11:258-266.
23. Rotger M, Tegude H, Colombo S, Cavassini M, Furrer H, Decosterd L, et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther 2007; 81:557-566.
24. Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U, et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001; 11:399-415.
25. Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D, et al. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer 2010; 102:1003-1009.
26. Ekhart C, Doodeman VD, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD. Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa. Br J Clin Pharmacol 2009; 67:50-60.
27. Hofmann MH, Blievernicht JK, Klein K, Saussele T, Schaeffeler E, Schwab M, et al. Aberrant splicing caused by single nucleotide polymorphism c.516G > T [Q172H], a marker of CYP2B66, is responsible for decreased expression and activity of CYP2B6 in liver. J Pharmacol Exp Ther 2008; 325:284-292.
28. Bunten H, Liang WJ, Pounder DJ, Seneviratne C, Osselton D. OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths. Clin Pharmacol Ther 2010; 88:383-389.
29. Wang SC, Ho IK, Tsou HH, Tian JN, Hsiao CF, Chen CH, et al. CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer. J Clin Psychopharmacol 2011; 31:463-469.
30. Levran O, Peles E, Hamon S, Randesi M, Adelson M, Kreek MJ. CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addict Biol 2011. doi: 10.1111/j.1369-1600.2011.00349.x.
31. Carr DF, la Porte CJ, Pirmohamed M, Owen A, Cortes CP. Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort. J Antimicrob Chemother 2010; 65:1889-1893.
32. Lamba V, Lamba J, Yasuda K, Strom S, Davila J, Hancock ML, et al. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther 2003; 307:906-922.
33. Zukunft J, Lang T, Richter T, Hirsch-Ernst KI, Nussler AK, Klein K, et al. A natural CYP2B6 TATA box polymorphism (-82T-C) leading to enhanced transcription and relocation of the transcriptional start site. Mol Pharmacol 2005; 67:1772-1782.
34. Klein K, Lang T, Saussele T, Barbosa-Sicard E, Schunck WH, Eichelbaum M, et al. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet Genomics 2005; 15:861-873.
35. Wang J, Sonnerborg A, Rane A, Josephson F, Lundgren S, Stahle L, et al. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics 2006; 16:191-198.
36. Gatanaga H, Hayashida T, Tsuchiya K, Yoshino M, Kuwahara T, Tsukada H, et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6&z.ast;6 and &z.ast;26. Clin Infect Dis 2007; 45: 1230-1237.
37. Kirchheiner J, Klein C, Meineke I, Sasse J, Zanger UM, Murdter TE, et al. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 2003; 13:619-626.